US Patent

US9562017 — Hydrogen sulfate salt

Method of Use · Assigned to AstraZeneca AB · Expires 2026-12-12 · 1y remaining

Vulnerability score 80/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects the hydrogen sulfate salt and various forms of Compound 1, as well as processes for preparing them.

USPTO Abstract

The present invention relates to Compound 1 hydrogen sulfate salt and solvates, crystalline forms and amorphous forms thereof, and to processes for their preparation.

Drugs covered by this patent

selumetinib-sulfate (SELUMETINIB SULFATE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-4357`	—	selumetinib-sulfate
`U-4357`	—	selumetinib-sulfate
`U-4357`	—	selumetinib-sulfate
`U-4357`	—	selumetinib-sulfate

Patent Metadata

Patent number: US9562017
Jurisdiction: US
Classification: Method of Use
Expires: 2026-12-12
Drug substance claim: Yes
Drug product claim: No
Assignee: AstraZeneca AB
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.